| Cat.No. | Name | Information |
|---|---|---|
| M40595 | Pidilizumab | Pidilizumab is a monoclonal antibody to PD-1 that can be used in studies related to diffuse large B-cell lymphoma (DLBCL). |
| M40594 | Genolimzumab | Genolimzumab is a PD-1 monoclonal antibody that can be used in studies related to peripheral T-cell lymphoma (PTCL). |
| M40593 | Brolucizumab | Brolucizumab is a humanized single-chain anti-VEGF-A variable antibody fragment (scFv) that can be used in studies related to macular degeneration. |
| M40592 | Certolizumab | Certolizumab is a recombinant, polyethylene glycolated, antigen-binding fragment of a humanized monoclonal antibody that selectively targets and neutralizes tumor necrosis factor (TNF)-alpha, and may be used in psoriasis-related studies. |
| M40552 | Osemitamab | Osemitamab (TST001) is a recombinant humanized, IgG1 antibody targeting CLDN18.2, consisting of the human mouse monoclonal TST001 γ-1 chain polymerized via disulfide bonding with the human mouse monoclonal TST001 κ-chain dimer (ACI). It can be used in studies related to bile duct tumors. |
| M31386 | Epcoritamab | Epcoritamab is a novel bispecific IgG1k/λ antibody targeting CD3 and CD20 that activates T cells and directs them to kill malignant CD20+ B cells.Epcoritamab has antitumor activity and may be used in studies related to RR diffuse large B-cell lymphoma (DLBCL). |
| M31300 | Faricimab | Faricimab is a bispecific antibody targeting Ang II and VEGF-A for studies related to eye disease and cardiovascular disease. |
| M31299 | Zebituzumab | Zebituzumab (zebituzumab) is a recombinant human-mouse chimeric anti-CD20 monoclonal antibody that can be used in studies related to CD20-positive diffuse large B-cell lymphoma. |
| M31121 | Dinutuximab | Dinutuximab is an anti-disialytic ganglioside antigen (GD2) antibody with anticancer activity for studies related to pediatric neuroblastoma. |
| M25443 | Necitumumab | Necitumumab is a second-generation fully humanized immunoglobulin G1 (IgG1), epidermal growth factor (EGFR) receptor monoclonal antibody that specifically blocks the ligand binding site of EGFR. |
| M25387 | Daclizumab | Daclizumab (Zenapax) is a humanized, monoclonal antibody that blocks CD25 (α-subunit of the high-affinity interleukin-2 receptor (IL-2R-HA)). Daclizumab (Zenapax) reversibly binds to CD25and prevents the interaction of IL-2 with the IL-2R-HA. |
| M25367 | Amlitelimab | Amlitelimab is a potential best-in-class (mAb) anti-OX40 ligand (OX40L) monoclonal antibody.Amlitelimab inhibits OX40-OX40L interaction and may be used in studies related to atopic dermatitis. |
| M25342 | Pucotenlimab | Pucotenlimab (HX008) is a humanized immunoglobulin G4 (IgG4) anti programmed cell death protein 1 (anti-PD-1) monoclonal antibody. Pucotenlimab can be used for the research of tumor. |
| M25328 | Latozinemab | Latozinemab (AL001) is a recombinant humanized anti-Sortilin monoclonal antibody. Latozinemab effectively binds Sortilin with a high affinity and blocks the interaction between progranulin protein (PGRN) and Sortilin receptor. Latozinemab has the potential for progranulin gene (GRN) mutations causative of Frontotemporal dementia (FTD) (FTD-GRN) research. |
| M25310 | Solanezumab | Solanezumab is a humanized monoclonal IgG1 antibody directed against the mid-domain of the amyloid-β (Aβ) peptide. Solanezumab has the potential for the research of Alzheimer’s disease. |
| M25309 | Lebrikizumab | Lebrikizumab is a humanized monoclonal antibody to IgG4κ that binds with high affinity and specificity to interleukin 13 (IL-13) and inhibits its function, thereby preventing the formation of the IL-13Rα1/IL-4Rα complex and inhibiting the signaling pathway mediated by this receptor complex.Lebrikizumab has been used in asthma and atopic dermatitis studies. Lebrikizumab may be used in asthma and atopic dermatitis studies. |
| M25306 | Cixutumumab | Cixutumumab (IMC-A12) is a humanized anti-IGF-1R monoclonal antibody with high affinity that inhibits ligand-dependent receptor activation and downstream signaling. Cixutumumab also mediates the internalization and degradation of IGF-IR. Cixutumumab shows broad-spectrum anti-tumour activity and can be used in studies of cancers such as lung cancer, malignancies, leukaemia, non-small cell lung cancer and prostate cancer. |
| M25301 | Eldelumab | Eldelumab (BMS-936557) is a humanised anti-CXCL10 (IP-10) monoclonal antibody (IgG1 type). Eldelumab selectively binds to CXCL10 and blocks CXCL10-induced calcium flux and cell migration. Eldelumab can be used in studies of autoimmune and auto-inflammatory diseases such as rheumatoid arthritis, ulcerative colitis and crohn's disease. |
| M25296 | Figitumumab | Figitumumab (CP-751871) is a potent and fully human monoclonal anti–insulin-like growth factor 1 receptor (IGF1R) antibody. Figitumumab prevents IGF1 from binding to IGF1R with an IC50 of 1.8 nM. |
| M25294 | Robatumumab | Robatumumab (Sch 717454) is an anti-human IGF-1R (insulin-like growth factor receptor-1) antibody. Robatumumab shows anti-tumor activity and anti-proliferative activity to cancer cells. Robatumumab can be used in osteosarcoma and Ewing sarcoma research. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
